Table 1.
Descriptive Characteristics of the Study Cohort, Stratified by Admission Date
| Patient characteristics | Pre-COVID pandemic (February 1, 2020 to March 15, 2020) n = 123 |
During COVID pandemic (March 16, 2020 to April 27, 2020) n = 88 |
P value |
|---|---|---|---|
| Age, median (IQR) | 67.9 (59.2–80) | 70.1 (60–77) | .6184 |
| Sex, female, n (%) | 52 (42.3) | 32 (36.4) | .387 |
| Race/ethnicity | .029 | ||
| Non-Hispanic white | 27 (22.0) | 7 (7.9) | |
| Non-Hispanic black | 22 (17.9) | 19 (21.6) | |
| Hispanic | 57 (46.3) | 53 (60.2) | |
| Other/unknown | 17 (13.8) | 9 (10.2) | |
| Outpatient medications, n (%), n=191 | |||
| Aspirin | 40 (34.2) | 28 (29.2) | .721 |
| NSAID | 18 (15.4) | 6 (8.1) | .059 |
| Anticoagulant | 21 (18.0) | 21 (23.9) | .299 |
| Antiplatelet | 9 (7.7) | 9 (10.2) | .526 |
| Laboratory values on admission, median (IQR) | |||
| Hemoglobin, g/dL, n=196 | 10.1 (7.6–12.3) | 8.75 (5.8–11.35) | .0188 |
| Platelet, count/μL, n=196 | 239 (185–325) | 197 (121.5–281) | .0083 |
| INR, n=161 | 1.1 (1.1–1.3) | 1.25 (1.1–1.7) | .0094 |
| PTT, s, n=160 | 30.95 (27.2–34.3) | 32.55 (28.2–36.4) | .0537 |
| BUN, mg/dL, n=196 | 19.5 (14–36) | 25 (15.5–39.5) | .0454 |
| Creatinine, mg/dL, n=196 | 0.93 (0.72–1.31) | 1.155 (0.82–1.965) | .0057 |
| Albumin, g/dL, n=177 | 3.6 (3.2–4.1) | 3.4 (3–3.9) | .0977 |
| SARS-CoV-2 detected, n (%), n=197 | 2 (1.6) | 38 (43.2) | <.001 |
| ICU admission during hospitalization, n (%) | 18 (14.6) | 14 (16.9) | .698 |
| Hospital length of stay, median (IQR) | 4 (3–7) | 5.5 (3–9) | .0043 |
| Hospital length of stay at/above median, n (%) | 55 (44.72) | 58 (65.9) | .002 |
| Number of transfusion(s), median (IQR) | 0 (0–2) | 1 (0–3) | .0152 |
| Any transfusions during admission, n (%) | 53 (43.1) | 52 (59.1) | .022 |
| PPI received during admission, n (%) | 101 (82.1) | 85 (88.2) | .001 |
| Endoscopy performed, n (%) | 62 (50.4) | 25 (28.4) | .001 |
| Inpatient mortality, n (%) | 11 (8.9) | 9 (10.2) | .754 |
BUN, blood urea nitrogen; ICU, intensive care unit; INR, International Normalized Ratio; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor; PTT, partial thromboplastin time.